The Centre for Drug Development portfolio

Biologics

Agent (Trial)	Target or technology	Partnerships	Indications	Phase
KJ103	Antibody TROP2	KisoJi Biotechnology	Solid tumours	Exploratory

NVG222	BITE ROR1, CD3	NovalGen	Haematological	Preclinical

ALETA001	Protein CD19, CD20	Aleta Biotherapeutics	Lymphoma	Phase 1

ASTVAC2	Vaccine LAMP, hTERT	Lineage Cell Therapeutics	Lung	Phase 1

MOv18 IgE	Antibody α-folate R	King's College London	Solid tumours	Phase 1

UCB4594	Antibody HLA-G1	UCB	Solid tumours	Phase 1

HMBD001	Antibody HER3	Hummingbird Bioscience	HER3 positive solid tumours, prostate	Phase 1/2

VTP-600 (MAGE)	Vaccine MAGE3, NY-ESO-1	Barinthus Biotechnology and Ludwig Institute for Cancer Research	Lung	Phase 1/2

Atezolizumab (DETERMINE )	Antibody PDL1	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancer	Phase 2

Trastuzumab + Pertuzumab (DETERMINE)	Antibody combination HER2	University of Manchester and Roche	Rare paediatric, teenage and young adult, and  adult cancer	Phase 2

Ginisortamab (UCB6114)	Antibody Gremlin1	UCB	Pancreatic	Phase 2

Agent (Trial)	Target	Partnerships	Indications	Phase
BT1718	MT1-MMP	Bicycle Therapeutics	Lung	Phase 1/2

HTL0039732	EP4	Nxera	Solid tumours	Phase 1/2

LY3143921	Cdc7	Lilly	Solid tumours	Phase 1/2

TT702 (CURATE)	Adenosine, A2BR	Teon Therapeutics	Solid tumours	Phase 1/2

Alectinib (DETERMINE)	ALK, TK1	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancers	Phase 2

Capmatinib (DETERMINE)	CMET, HGFR	University of Manchester and   Roche	Rare adult cancer	Phase 2

Entrectinib (DETERMINE)	ROS1, TLK, ALK	University of Manchester and Roche	Rare paediatric, teenage and young adult, and adult cancers	Phase 2

Vemurafenib + cobimetinib (DETERMINE)	BRAF, MAP, MEK	University of Manchester and Roche	Rare adult cancers	Phase 2